Month: June 2025

New episode spotlights the severe burden of Netherton Syndrome in infants and children, reinforcing the need for effective pediatric treatments ASHBURN, Va., June 26, 2025 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release of a new episode in its NETHERTON NOW video series. The episode features Professor Jemima Mellerio, a recognized authority in dermatology and genetic skin disorders. In the video, Professor Mellerio, Consultant Dermatologist at St John’s Institute of Dermatology at Guy’s and St Thomas’ NHS Foundation Trust and Honorary Chair of Paediatric Dermatology at King’s College London, shares her perspective on the complex and life-threatening challenges of Netherton...

Collaboration with French MedTech company, TISSIUM, has resulted in FDA approval for unique 3D-printed polymeric solution for repair of peripheral nerve damage 3D Systems’ bioprinting system enabled production of a 3D-printed bioabsorbable medical device leveraging TISSIUM’s proprietary biomorphic programable polymers—a major industry milestone that sets new standard for high resolution elastomeric 3D-printed medical implants Builds on 3D Systems’ pioneering work to develop additive manufacturing solutions for regenerative medicine applications 3D Systems’ solutions accelerating additive manufacturing use in bioprinting—total market anticipated to reach more than $2 billion by end of 2029ROCK HILL, South Carolina, June 26, 2025 (GLOBE NEWSWIRE) — Today, 3D Systems (NYSE: DDD) announced that its 3D bioprinting technologies have...

Geneva, Switzerland, June 26, 2025 (GLOBE NEWSWIRE) — SEALSQ’s unique value proposition integrates PKI with Quantum-Resistant Cryptography and Post-Quantum Secure Hardware SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced expanded capabilities to support the rapidly evolving Internet of Medical Things (IoMT) landscape. SEALSQ’s technologies provide essential security components for applications that secure communications, authenticate devices, and enforce compliance with next-generation digital health frameworks.The IoMT represents a vast network of interconnected medical devices, sensors, software, and healthcare systems utilizing internet connectivity to...

Important Study Shows Vivos Technology to be a Safe and Highly Effective, Non-Surgical Alternative to Surgical Removal of Tonsils and Adenoids in Children LITTLETON, Colo., June 26, 2025 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced that the European Journal of Pediatrics has published the results of a groundbreaking multicenter clinical trial evidencing positive results for the treatment of OSA in children using Vivos’ patented Daytime-Nighttime Appliance (DNA). The study importantly noted that “This is the first study demonstrating that the [Vivos DNA] device is safe and efficacious in treating children with OSA.” In September 2024, Vivos received an unprecedented FDA 510(k) clearance for...

Spetner Reports 95% Revenue Growth and Tripled Net Income in Q1 2025, Highlighting Strong Profitability and Cash Flows Ahead of Planned Acquisition LAKEWOOD, NJ, June 26, 2025 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: RELI) (“Reliance,” “we,” “us,” “our” or the “Company”) today highlighted the strong preliminary unaudited financial results of Spetner Associates, Inc. (“Spetner”) for the first quarter ended March 31, 2025. As previously announced, Reliance has entered into a definitive agreement to acquire Spetner, and the transaction continues to advance toward closing. Spetner’s Q1 2025 Financial Highlights (Unaudited):Revenue increased by more than 95% year-over-year to approximately $5.16 million, compared with $2.64 million in Q1 2024. Operating income margin grew by 29% year-over-year to 74% from 46% in Q1...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) — via InvestorWire — LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within the Dynamic Brand Portfolio @ IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Near-Term Production Assets Gain Traction amid Historic Gold Price Surge,” please visit: https://ibn.fm/yr5Zp Gold’s remarkable surge — driven by an unstable U.S. fiscal policy and rising inflation — has propelled prices beyond the historic US$3,300 per ounce threshold in early 2025 and sparked even more bullish outlooks. Many experts are forecasting...

TORONTO, June 26, 2025 (GLOBE NEWSWIRE) — Canadian Life Companies Split Corp. (“the Company”) is pleased to announce it has completed the overnight offering of Preferred Shares and Class A Shares of the Company. Total gross proceeds of the offering were $40.0 million, bringing the Company’s net assets to approximately $217.9 million. The shares will begin trading on the Toronto Stock Exchange under the existing symbols of LFE.PR.B (Preferred Shares) and LFE (Class A Shares). The Preferred Shares were offered at a price of $10.55 per Preferred Share to yield 6.64% and the Class A Shares were offered at a price of $6.35 per Class A Share to yield 18.90%. The offering was led by National Bank Financial Inc. The net proceeds of the offering will be used by the Company to invest in an actively managed portfolio primarily consisting...

GREENWICH, Conn., June 26, 2025 (GLOBE NEWSWIRE) — Stardust Power Inc. (NASDAQ: SDST) (the “Company”), an American developer of battery-grade lithium products, today announced that the underwriter of its previously announced public offering of common stock has exercised its option to purchase an additional 1,100,000 shares of Common Stock, resulting in additional gross proceeds of approximately $220,000. After giving effect to the exercise of the over-allotment option, the gross proceeds from the offering increased to approximately $4.52 million, before deducting underwriting fees and other estimated offering expenses payable by the Company. The exercise of the over-allotment option closed on June 25, 2025, subject to customary closing conditions. The proceeds from the over-allotment will support the completion of Stardust Power’s...

CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with existing and new healthcare focused institutional investors for the purchase and sale of 20,000,000 shares of its common stock (or common stock equivalents in lieu thereof) together with Series C warrants to purchase up to 20,000,000 shares of common stock (the “Series C Warrants”) and Series D warrants to purchase up to 20,000,000 shares of common stock (the “Series D Warrants”), at a combined offering price of $0.50...

The Company received $4.5 million in gross proceeds at the initial closing as consideration for the issuance of a $5.0 million convertible promissory note to the institutional investor Tel Aviv, Israel, June 26, 2025 (GLOBE NEWSWIRE) — Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, today announced that it has entered into a Securities Purchase Agreement (the “SPA”), with an institutional investor (the “Investor”), pursuant to which the Company may issue and sell, from time to time, convertible promissory notes (the “Promissory Notes”) in an aggregate principal amount of up to $100.0 million. Upon the signing of the SPA (the “Initial Closing”), the Company issued and sold to the Investor an initial $5.0 million Promissory Note...